New Job Opportunity

January 14, 2026 | New Job Opportunity

BD Invests $110M to Expand Syringe Production, Create 120 Jobs

BD,a leading global medical technology company, announced a $110 million investment to expand its production of prefillable syringes, helping accelerate biologic and GLP-1 drug delivery and supporting pharmaceutical reshoring in the U.S. This investment will bring BD Neopak™ Glass Prefillable Syringe production to Columbus, Nebraska, creating approximately 120 new jobs and reinforcing the company's supply resilience within its Pharmaceutical Systems portfolio. "This is good news for Nebraska," said Sen. Ricketts. "It has the potential to bring over 100 new jobs to our state. This investment further underscores BD's ongoing commitment to keep critical manufacturing in states like Nebraska. I appreciate BD's long-standing partnership with the Cornhusker State." "As demand for biologics and GLP-1s accelerates, BD is strengthening its American manufacturing footprint to support U.S.-based drug delivery innovation and supply chain resiliency," said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. "This investment in Nebraska, advances our long-term growth strategy and reflects our commitment to partnering with biopharmaceutical innovators as they bring advanced therapies to patients who require next-generation drug delivery solutions." Strategic Investments in Columbus, NebraskaBD is investing $100 million to establish BD Neopak™ Glass Prefillable Syringe production at its Columbus site, with supply expected to begin in mid-2026. This investment will also support additional line upgrades and capacity improvements across the site, ensuring BD can meet growing global demand for advanced injectable solutions. In addition, BD is investing $10 million to enhance cannula manufacturing capabilities at the site, and together these investments will add approximately 120 new jobs. This announcement builds on BD's recent investment of more than $35 million to expand prefilled flush syringe manufacturing in Columbus, which will add approximately 50 new jobs and strengthen the supply of critical medical devices to health care providers across the U.S. BD Columbus has been a strategic site within BD's global manufacturing network for more than 75 years and is home to part of the company's vertically integrated cannula manufacturing operations, including design and production. As the largest medical device manufacturer in the United States, these investments are part of BD's commitment to invest more than $2.5 billion in U.S. manufacturing capabilities over the next five years.

January 14, 2026 | New Job Opportunity

Hammes Expands Healthcare Footprint with Scottsdale Medical Office

Hammes, a national real estate consulting, development, investment and management firm, is developing a new 34,000-square-foot medical office building in Scottsdale, Arizona, in partnership with Phoenix-based NOVO Development. The medical office building will serve as an anchor component of the new 43-acre Sierra Bloom mixed-use wellness campus. "NOVO is honored to have been selected by Abrazo to deliver this new location for ASMC," said Kurt Rosene of NOVO Development. "We are excited to partner with Hammes to develop this first-phase medical office building at Sierra Bloom." The medical office building is anticipated to be completed in the third quarter of 2026, with a topping out ceremony slated for late March. The Sierra Bloom medical office building represents another investment in the region for Hammes, which completed a 48,000-square-foot medical office building in Buckeye, Arizona, in 2024. "This project reflects our continued commitment to developing high-quality healthcare environments that support providers and improve patient access to specialized medical services," said Hammes Partners Senior Vice President Steve Buckeridge. "We're proud to partner with NOVO Development and Abrazo on this state-of-the-art facility."

January 09, 2026 | New Job Opportunity

Global Health Sciences Expansion Fuels Job Creation Across Manufacturing, R&D and Services

The global health sciences industry continues to witness strong momentum in facility expansions, new manufacturing hubs, and regional investments, reinforcing its role as a key driver of high-value job creation. From medical devices and biopharmaceutical manufacturing to digital health, regulatory services, and workforce platforms, companies are scaling operations to meet rising global demand while strengthening supply chain resilience. Recent announcements from across the Americas, Europe, and Asia highlight how strategic investments are translating into thousands of new jobs for scientists, engineers, technicians, clinicians, and operations professionals. Costa Rica Strengthens Position as a Medical Device Manufacturing Hub Costa Rica has emerged as one of the world’s most dynamic centers for medical device manufacturing and exports, according to a study by the Trade & Investment Promotion Agency of Costa Rica (PROCOMER). Key indicators of growth include: 22% average annual growth in medical device exports (2020–2024) Exports reaching $8.675 billion, ranking the country 10th globally 52% of all new Latin American medical device investments Over 100 multinational companies operating in the sector Medical devices now represent 48% of Costa Rica’s total goods exports, supporting jobs across advanced manufacturing, engineering, quality systems, and logistics, and positioning the country as a major employment hub in Latin America. Fujifilm Expands Biopharma Manufacturing Capacity in Japan FUJIFILM Corporation has completed one of Japan’s largest bio CDMO facilities at its Toyama Second Factory. The new site is Fujifilm’s first antibody drug manufacturing plant in Japan and is expected to become operational in 2027. Facility highlights: 2 × 5,000-liter and 2 × 2,000-liter single-use bioreactors Modular kojoX™ facility design to accelerate technology transfer End-to-end services from drug substance to finished goods The facility will serve as Fujifilm’s bio CDMO hub in Asia, creating demand for skilled professionals in biologics manufacturing, quality assurance, engineering, and packaging. Samsung Biologics Secures U.S. Footprint, Retains 500+ Jobs Samsung Biologics announced the acquisition of GSK’s Rockville manufacturing assets for $280 million, securing its first U.S.-based manufacturing site. The deal is expected to close by the end of Q1 2026. Workforce impact includes: Retention of more than 500 employees Continued production of existing biologic medicines Planned investments to expand capacity and upgrade technology The move strengthens Samsung Biologics’ global manufacturing network and ensures long-term job stability at the U.S. site. Identiv Completes Manufacturing Transition to Thailand Identiv has successfully completed its manufacturing transition from Singapore to a new facility in Bangkok, Thailand, as part of its long-term operational strategy. Key benefits: Access to a skilled and cost-competitive workforce Enhanced efficiency and scalability Strengthened leadership in advanced IoT manufacturing The transition supports new hiring across engineering, production, and quality functions. Alnylam’s $250M Expansion Drives Advanced Manufacturing Jobs Alnylam Pharmaceuticals has announced a $250 million expansion of its Norton, Massachusetts facility to support its next-generation siRNA enzymatic-ligation manufacturing platform (siRELIS™). Expansion highlights: Increased capacity for future RNAi product launches Reduced production costs through advanced manufacturing Creation of high-skill roles in automation, bioprocessing, and regulatory operations The project reinforces Massachusetts’ status as a global life sciences employment hub. INCOG BioPharma to Add Nearly 1,000 Jobs in Indiana INCOG BioPharma Services is investing approximately $200 million to expand its injectable drug product manufacturing facility in Fishers, Indiana. Employment outlook: Nearly 1,000 employees expected by 2030 High-value jobs in manufacturing, quality, engineering, and operations Expanded CDMO capacity to meet global biopharma demand ProPharma Expands India Operations with Hyderabad Office ProPharma has inaugurated a new office in Hyderabad, India, supporting its continued growth across regulatory, clinical, and compliance services. Expansion benefits: Capacity for additional hiring across multiple service lines Strengthened Global Capability Center (GCC) presence Modern, collaborative workspace for life sciences professionals Onkos Surgical Opens New Jersey Innovation Center Onkos Surgical has opened the NanoCept Innovation Center in Bridgewater Township, New Jersey, enabling in-house innovation and expanded production capacity. Facility features: 4,600-square-foot innovation and manufacturing site Supports NanoCept® Antibacterial Technology New roles for chemists, engineers, and R&D specialists Eli Lilly’s $6B Investment Brings High-Skill Jobs to Alabama Eli Lilly and Company plans to invest over $6 billion in a new manufacturing facility in Huntsville, Alabama. Job creation includes: 450 permanent high-value jobs 3,000 construction jobs during build-out Strengthened U.S. API manufacturing and supply chain resilience Conclusion The steady expansion of manufacturing facilities, innovation centers, and service hubs across the global health sciences industry reflects a strong commitment to long-term growth and workforce development. As companies invest in advanced technologies, localized production, and resilient supply chains, job creation remains a central outcome. For professionals across biopharma, medical devices, healthcare services, and digital health, the current expansion cycle presents sustained opportunities to build meaningful, future-ready careers in a rapidly evolving global industry.

December 30, 2025 | New Job Opportunity

Costa Rica Emerges as a Global Hub for Medical Device Manufacturing and Exports

A new analysis of the medical devices sector confirms that Costa Rica has emerged as one of the world's most dynamic, innovative and competitive hubs for the manufacturing and export of medical technology. According to The World's Health Is Made in Costa Rica, a study conducted by the Trade & Investment Promotion Agency of Costa Rica (PROCOMER), the country recorded an average annual growth rate of 22% in medical device exports between 2020 and 2024, reaching US$8.675 billion and consolidating its position as the 10th largest exporter globally and the world's leading exporter on a per-capita basis. Costa Rica also accounts for 52% of all new investment in the medical devices industry in Latin America and has become the third-largest global recipient of foreign direct investment (FDI) projects in this sector. Today, more than 100 companies from the United States, Germany, Ireland, Sweden, Japan, Spain and other markets operate in the country, covering specialized areas such as endoscopy, cardiology, orthopedics, ophthalmology, diagnostics and advanced surgical solutions. This performance reflects Costa Rica's transition toward an economy driven by innovation, advanced manufacturing and high value-added production. Medical devices now represent 48% of the country's total goods exports and are shipped to markets across the Americas, Europe and Asia. PROCOMER data show that, as of October this year, exports from the sector reached US$9.199 billion, representing 30% year-on-year growth and already surpassing the total value exported throughout 2024. "Costa Rica exports diversity—of talent, capabilities and solutions that improve lives around the world. This industry proves that our ability to innovate and deliver cutting-edge technology knows no borders. Costa Rica not only attracts specialized investment; it manufactures and exports products with exceptionally high value added, supported by a unique value proposition that combines stability, skilled talent and a strong commitment to quality," said Laura López, CEO of PROCOMER. Currently, Costa Rica exports 164 different medical device products to 88 markets, with key categories including needles, catheters and cannulas (41.5%), other medical devices (30.8%) and medical prostheses (14.5%). The United States remains the main destination, accounting for 66.5% of exports, followed by the Netherlands and Belgium. The country's local supply chain has also strengthened significantly, supported by specialized providers in tooling, metalworking, plastics, sterilization, contract manufacturing, clean rooms and precision assembly. This ecosystem enables efficient operations while fostering knowledge transfer and raising industry standards among domestic suppliers nationwide. A reliable and stable ecosystem for global investment The PROCOMER study highlights that Costa Rica's leadership in medical devices is underpinned by a combination of key factors: Economic, political and social stability A competitive, renewable electricity matrix Highly skilled human talent Advanced productive and logistics infrastructure Strong local supply-chain linkages Three decades of accumulated experience in advanced manufacturing Together, these strengths have allowed Costa Rica to move from basic manufacturing to highly precise, technologically sophisticated products, quadrupling the number of high-tech medical products exported in less than a decade. The consolidation of the medical devices sector demonstrates its role as a structural pillar of Costa Rica's development model. Its multiplier effects are reflected in higher-quality jobs, deeper supplier integration, greater technology transfer and an expanding presence in global healthcare value chains.

December 24, 2025 | New Job Opportunity

Fujifilm Accelerates Biopharma Manufacturing with New Japan CDMO Facility

FUJIFILM Corporation announced the completion of one of Japan’s largest bio CDMOfacilities (the new plant) at the Toyama Second Factory of FUJIFILM Toyama Chemical and held a completion ceremony to mark the occasion. The new plant is the company’s first antibody drug manufacturing plant in Japan and is scheduled to be operational in 2027. Together with an adjacent plant currently under construction, Fujifilm will establish end-to-end manufacturing services covering drug substance manufacturing through finished goods and packaging, serving as the company’s bio CDMO hub in Asia. The new plant is equipped with 2 x 5,000 liters (L) mammalian cell culture bioreactors, which are among the world’s largest single-use bioreactors, as well as 2 x 2,000 L bioreactors. To ensure high quality and faster technology transfer between sites while reducing construction lead time, the facility adopts the “kojoX™” modular facility design approach, which standardizes equipment and quality management systems with the FUJIFILM Biotechnologies’ site in the UK. Fujifilm is establishing a globally competitive bio CDMO site in Japan that enables rapid and efficient contract manufacturing of biopharmaceuticals, such as antibody drugs and antibody-drug conjugates (ADCs). This new site leverages FUJIFILM Toyama Chemical’s aseptic manufacturing expertise, cultivated through injectable antibiotic production, and combines it with the expertise of FUJIFILM Biotechnologies, which operates bio CDMO services in Europe and the U.S. In Japan, demand for biopharmaceuticals continues to grow, yet many pharmaceutical companies outsource manufacturing to overseas, creating challenges in the speed of process development and technology transfer. To address these issues, Fujifilm is building a manufacturing facility in Japan that meets rigorous global quality standards, aiming to reduce the burden of technology transfer caused by language and geographical barriers, accelerate market launch, and contribute to a stable supply of biopharmaceuticals. The new plant, together with an adjacent plant under construction for mRNA therapeutics and vaccines, has been selected by Japan’s Ministry of Economy, Trade, and Industry for the project of “Developing Biopharmaceutical Manufacturing Sites to Strengthen Vaccine Production.” This dual-use designation will allow the facility to manufacture biopharmaceuticals during normal times and switch to vaccine production in the event of a pandemic.

December 22, 2025 | New Job Opportunity

Samsung Biologics Acquires U.S. Facility From GSK, Securing 500+ Jobs

Samsung Biologics, a leading contract development and manufacturing organization, announced that its wholly owned U.S. subsidiary, Samsung Biologics America, has entered into a definitive agreement to acquire 100% of Human Genome Sciences from GSK . This strategic move secures Samsung Biologics' first U.S.-based manufacturing site, a significant expansion of the company's global footprint and its long-term commitment to the U.S. market. Existing products will continue to be manufactured at the site, and Samsung Biologics plans to make additional investments to expand the site's capacity and upgrade technology to further support a more resilient U.S. supply chain for critical biologic medicines. Under the terms of the agreement, with closing anticipated toward the end of Q1 of 2026, Samsung Biologics will acquire the Rockville assets for USD 280 million. The company will also retain more than 500 employees at the site to ensure operational continuity and stability. By integrating this facility into our global network, Samsung Biologics will provide clients with flexible, multi-site options in both the U.S. and Korea to ensure that live-saving therapeutics are reliably available to American patients. Samsung Biologics has established a proven track record of operational and construction excellence through on-time completion of its Bio Campus I and II, and also recently secured land for Bio Campus III, which will house distinct R&D and manufacturing programs for new modalities. With 785,000 liters of capacity across five plants, the industry's leading capacity, Samsung Biologics continues to advance its diversified portfolio spanning monoclonal antibodies, antibody-drug conjugates (ADCs), mRNA, organoid-based services, and next-generation therapies. "This landmark acquisition is a testament to our unwavering commitment to advancing global healthcare and bolstering our manufacturing capabilities in the U.S. The investment will enable us to deepen our collaboration with federal, state, and local stakeholders to best serve our customers and partners while ensuring a reliable and stable supply of life-saving therapeutics," said John Rim, CEO and President of Samsung Biologics. "This marks an important step forward in our mission to achieve a better life through biomedicines, and we look forward to building on the legacy of this facility as we welcome experienced colleagues to the Samsung Biologics family and continue delivering innovative solutions that make a meaningful impact." Regis Simard, President, Global Supply Chain, GSK, said: "Today's agreement to divest the Rockville manufacturing site to our valued long-term partner, Samsung Biologics, will secure the manufacture of two important medicines on US soil for US patients and further build GSK's supply chain resilience. Along with GSK's recent commitment to invest $30bn in R&D and manufacturing in the US over the next 5 years, this deal enables us to further focus on building the agility, capacity and capability needed in our manufacturing network to deliver the next generation of specialty medicines and vaccines. I am confident in a positive partnership and future for the Rockville site." 

December 19, 2025 | New Job Opportunity

Identiv Completes Manufacturing Transition to Thailand, Strengthens Leadership in Advanced IoT Manufacturing

Identiv, Inc. a global leader in RFID- and BLE-enabled Internet of Things (IoT) solutions, announced the successful completion of its manufacturing transition from Singapore to its state-of-the-art facility in Bangkok, Thailand. The successful production transition to Thailand represents a significant achievement for the Perform pillar of Identiv's Perform, Accelerate, Transform (P-A-T) strategy, establishing a state-of-the-art and highly efficient manufacturing operation in a location known for its strong workforce and competitive cost structure. This strategic milestone is expected to drive operational excellence, while also positioning the company as an IoT industry leader in Multicomponent Manufacturing (MCM), the forward-looking production method critical for the next decade of advanced IoT applications. "The completion of our Thailand production transition is a foundational milestone for Identiv as a pure-play IoT company, marking the end of a successful two-year process and delivering on a key strategic objective for operational excellence," said Kirsten Newquist, CEO at Identiv. "By providing a state-of-the-art, high-quality and cost-efficient base, the Thailand facility is now the engine of our competitive advantage, engineered for the future of IoT and sustained, profitable growth." The Strategic Advantage of MCM at IdentivAs IoT applications expand from inventory management and asset tracking to complex, high-value applications such as real-time location tracking, condition monitoring, and advanced security, simple, single component inlays are evolving into more sophisticated, multi-component designs to deliver this data accurately and consistently. MCM is an important production method for this new era of IoT manufacturing, enabling the industrial-scale integration of various components, including chips, sensors, and batteries, into advanced RFID- and BLE-enabled tags. Identiv's Thailand facility is strategically positioned with this advanced MCM capability, enabling the Company to rapidly commercialize next-generation, high-value IoT solutions and support continued growth. "Multicomponent manufacturing is not merely an assembly method; it is the orchestration of interdependent disciplines, including product design, process engineering, material science, and testing," said Dr. Manfred Mueller, Chief Strategy Officer at Identiv. "The decade of experience our teams have in refining these parameters across thousands of production runs is a key competitive advantage for Identiv. This expertise is what allows us to rapidly prototype and commercialize complex systems for critical high-value applications, cementing our role as the infrastructure layer shaping IoT's future."

December 18, 2025 | New Job Opportunity

Alnylam’s $250M Massachusetts Expansion to Create Jobs, Strengthen Global Life Sciences Hub

Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The Company is preparing to invest $250 million to advance what is poised to become the industry’s first fully dedicated, proprietary, siRNA enzymatic-ligation manufacturing facility. This investment is expected to meaningfully expand capacity, significantly reduce production costs, and position Alnylam to support future launches across its growing pipeline of potential new medicines. As part of the expansion, Alnylam also announced that this next-generation, scalable, enzymatic ligation manufacturing platform, siRELIS™, has been accepted into the U.S. Food and Drug Administration’s (FDA) Emerging Technology Program, accelerating dialogue with global health authorities on innovative manufacturing approaches for oligonucleotide-based medicines. This acceptance follows successful demonstration of Alnylam’s enzymatic ligation platform through production of pilot-scale batches of zilebesiran, which is being studied to reduce the risk of major adverse cardiovascular events in patients with hypertension (high blood pressure), and nucresiran, which is in development for the treatment of transthyretin-mediated amyloidosis (ATTR). “At this pivotal time with our expanding pipeline of RNAi therapeutics, Alnylam is accelerating development of siRNA manufacturing and changing what’s possible in a single facility,” said Yvonne Greenstreet, M.D., MBA, Chief Executive Officer of Alnylam. “This advance will be a critical enabler in the scaling of our pipeline to include potential treatments for diseases such as hypertension, type 2 diabetes, and obesity.” Expansion in Norton, MAThe $250 million expansion of Alnylam’s 200,000 sq. ft. Norton facility will increase its capabilities to locally produce both clinical and commercial supply of siRNA oligonucleotide drug substance for patients around the world. The facility, which opened in 2021, has played a key role in the growth of Alnylam’s clinical pipeline and acts as a pipeline accelerator for early-stage programs, including programs targeting different tissue types (e.g., liver, CNS, muscle, adipose, etc.). This expansion will strengthen Massachusetts’ position as a global hub of life sciences innovation. Construction is underway, with new capabilities expected to become fully operational by late 2027. “Alnylam represents the world-class health care innovation Massachusetts is known for. Alnylam has been a leader in life sciences in our state for over two decades,” said Governor Maura Healey. “Their scientific breakthroughs in siRNA manufacturing have transformed care by providing RNAi therapeutics to people who need it most, while creating thousands of jobs across our state. We're excited to support their growth through the expansion of a manufacturing facility in Southeastern Mass., and we're grateful for their continued investment in Massachusetts.” “Alnylam’s continued investment in Massachusetts underscores the Commonwealth’s role as a global leader in biomanufacturing,” said Dr. Kirk Taylor, President and CEO of the Massachusetts Life Sciences Center (MLSC). “This expansion will bring high-quality jobs to this area and ensure patients worldwide have the opportunity to benefit from medicines made right here in Massachusetts. We look forward to deepening our partnership as we work together to advance the thriving life sciences ecosystem here in the Commonwealth.” A Breakthrough in Manufacturing at ScaleAlnylam’s siRELIS™ platform builds RNAi therapeutics more efficiently using fewer materials and plant resources, and greatly expands capacity – making large-scale, sustainable production possible. “Manufacturing oligonucleotide-based medicines is highly complex, and the current manufacturing technology will struggle to meet increased demand. We have successfully applied a reproducible, less time-intensive process that increases throughput while maintaining the highest quality standards,” said Timothy Maines, Chief Technical Operations and Quality Officer at Alnylam. “The expansion of our Norton facility presents an opportunity to reinvent what’s possible in oligonucleotide manufacturing.”

December 17, 2025 | New Job Opportunity

INCOG BioPharma to add nearly 1,000 jobs through $200M manufacturing expansion

INCOG BioPharma Services, a leading contract development and manufacturing organization (CDMO), announced another major expansion with an investment of approximately $200 million in its manufacturing facility in Fishers, Indiana. This investment will significantly increase the company's injectable drug product manufacturing capacity. By 2030, INCOG expects to employ nearly 1,000 people at its Fishers campus. These high-paying, high-value jobs are set to establish INCOG as one of the preeminent employers within Indiana's life sciences industry. "The continued demand from our global biopharma partners and our team's ability to deliver create the opportunity for this next level of investment and expansion," said Cory Lewis, CEO of INCOG BioPharma. "Committing another $200 million and employing nearly 1,000 team members by 2030 underscores our dedication to continue providing world-class, flexible manufacturing capacity while creating generational opportunities for the talented workforce here in central Indiana. This is a vote of confidence in our team, our quality, and our future." The accelerated investment is made possible by incentives offered by the State of Indiana. "INCOG BioPharma's expansion is yet another example of Indiana leading in life sciences and advanced manufacturing. This major investment further positions us as one of the nation's top hubs for innovative drug development and will bring hundreds of new, high-paying jobs to our state. I'm proud to see companies like INCOG choose Indiana as the place to grow," said Indiana Governor Mike Braun. The expansion is scheduled to begin in early 2026, establishing the 21‑acre campus as a premier global manufacturing hub for injectable biopharmaceuticals, with approximately 300,000 square feet of purpose‑built space. This investment also reinforces the long-standing partnership between INCOG BioPharma and the City of Fishers, anchoring the company's growth in the region. "In 2020, we committed to doubling down to make Fishers a life science hub. INCOG believed in our vision, and as they bring their third expansion to Fishers, we have delivered promises made to our community. Fishers is leading the state as an ideal home for life science firms, with more than $1 billion in investment committed across life science firms who call our city home," said Scott Fadness, Mayor of Fishers. "This massive new investment and the commitment to nearly 1,000 high-paying jobs will have a transformative impact on our community's economic landscape for decades to come. We are proud to support their mission to bring critical therapies to the world."

December 12, 2025 | New Job Opportunity

ProPharma Expands Global Footprint with New Hyderabad Office Launch

ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry and a portfolio company of Odyssey Investment Partners, announced the official inauguration of its new office in Hyderabad, India. Strategically located in Mindspace, at the heart of Hyderabad's technology corridor (HITEC City/Madhapur), the new office places ProPharma among the world's leading Global Capability Centers (GCCs) in the pharmaceutical industry. Mindspace is also the first commercial business park in Hyderabad to receive a Gold rating from the Indian Green Building Council (IGBC). The prominent placement of the ProPharma logo atop the building underscores the company's growing presence and brand visibility in India. The expansion supports ProPharma's continued growth trajectory by providing capacity for additional team members across multiple service lines and creating a modern, collaborative environment designed to inspire innovation and connection. More than 70 employees participated in the inaugural celebration. "This milestone represents an important step forward in ProPharma's global expansion," said Jason DeGoes, President, ProPharma. "Our new Hyderabad office strengthens our ability to deliver high-quality, integrated solutions for our clients around the world and reflects our commitment to building an exceptional environment for our teams." "We're proud to establish a world-class workspace in Hyderabad—one designed to foster creativity, efficiency, and collaboration," added Pavan Hemadri, Director of Business Operations, ProPharma. "This move enhances our ability to attract top local talent and better serve our clients across regulatory, clinical, and compliance domains." The new state-of-the-art facility features open, collaborative workspaces aligned with ProPharma's global culture of innovation and operational excellence. It also underscores ProPharma's long-term investment in India as a key hub supporting its worldwide operations.

Page 2 of 49

Featured Recruiters